Drug Profile
Lamivudine/raltegravir
Alternative Names: DUTREBIS; MK-0518/3TC; MK-0518B; Raltegravir/3TC; Raltegravir/lamivudineLatest Information Update: 03 Jul 2019
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antiretrovirals; Deoxyribonucleosides; Dideoxynucleosides; Naphthyridines; Organic chemicals; Pyrimidine nucleosides; Small molecules
- Mechanism of Action HIV integrase inhibitors; Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed HIV-1 infections
Most Recent Events
- 03 Jul 2019 Chemical structure information added
- 28 Jan 2019 Lamivudine/raltegravir is not yet available for HIV-1 infections in Eropean Union, Iceland, Liechtenstein and Norway (PO)
- 26 Mar 2015 Registered for HIV-1 infections (Combination therapy, In adolescents, In adults, In children) in European Union (PO)